A cancer-detection diagnostics company delivering 28% revenue growth and four consecutive quarterly earnings beats is disqualified from investment by quality scores below the minimum floor—free cash flow deeply negative at 69% of revenue, no established competitive moat, 15% short interest, and a single-asset pipeline concentrated entirely in one product—making the setup an avoid until fundamental quality criteria are met.
Thesis pillars
- Single Product Pipeline Concentration→Stable
- Perfect Earnings Beat Streak→Stable
- Cash Burning Quality Disqualifier→Stable
- +2 more pillars — see the Why tab for full reasoning
GRAIL, Inc. (GRAL) Stock Analysis
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $69.50: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: High short interest: 17%; Below-average business quality; Rich valuation.
GRAIL, Inc. sells Galleri, a multi-cancer early detection test that screens for cancer signals across 50+ types from a single blood draw using targeted DNA methylation analysis. The company sold over 185,000 Galleri tests in 2025 (475,000+ since the mid-2021 launch), with... Read more
Sell if holding. Engine safety override at $69.50: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: High short interest: 17%; Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.4/10, moderate confidence.
Passes 4/8 gates (news events none recent, earnings proximity 37d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: speculative.
About GRAIL, Inc.
About GRAIL, Inc.
GRAIL sold more than 185,000 Galleri multi-cancer early detection tests in 2025, bringing cumulative commercial volumes to over 475,000 since the mid-2021 launch, while reporting a net loss of $408.4 million and an accumulated deficit of $10.2 billion at December 31, 2025. The last module of a Pre-Market Approval application for Galleri was submitted to the FDA in January 2026, incorporating data from the PATHFINDER 2 Initial Results and the NHS-Galleri Prevalent Screening Round. Galleri constitutes substantially all of GRAIL's current revenue.
GRAIL sells Galleri as a laboratory developed test accessible to self-insured employers, digital health platforms, certain third-party payors, and life insurance providers in the United States; government reimbursement through Medicare and Medicaid was not in place as of December 31, 2025. In February 2026, a new U.S. law created a Medicare coverage benefit category for MCED tests, with CMS authorized to initiate coverage as early as January 1, 2029, phased in starting with those aged 50-65 and expanding by one year-age annually, subject to a CMS national coverage determination process. GRAIL also generates limited revenue from a precision oncology platform offered on a research-use-only basis to biopharmaceutical partners; in late 2025, one partner terminated a Phase 3 trial for which GRAIL's methylation technology was used as a potential companion diagnostic. The company's laboratory infrastructure processed over 800,000 tests across clinical and commercial programs through year-end 2025.
Show full overview
GRAIL faces multiple sequential regulatory gates before broad coverage could be achieved: the FDA PMA review, which can take several years from submission and may result in approval with limited indications; NHS England's evaluation of final NHS-Galleri Trial results, planned for sharing in mid-2026 under a joint steering committee process; and CMS rulemaking for the Medicare MCED benefit, potentially starting 2029. In February 2026, topline results from the NHS-Galleri Trial showed the primary endpoint of statistically significant combined Stage 3 and 4 reduction was not met, which the 10-K acknowledges may adversely affect coverage, reimbursement, and commercial adoption decisions. On June 1, 2026, GRAIL disclosed via Form 8-K the appointment of Dr. Joshua Ofman as Chief Executive Officer with annual base salary of $800,000, taking leadership as the PMA review proceeds.
See also: Healthcare · Diagnostics & Research
From GRAIL, Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-07-07Recent Developments — GRAIL, Inc.
Latest news
- NEWS Goldman Sachs Initiates Coverage On GRAIL with Neutral Rating, Announces Price Target of $60 — benzinga Jun 5, 2026
- NEWS TD Cowen Maintains Buy on GRAIL, Raises Price Target to $69 — benzinga May 6, 2026 positive
- NEWS Piper Sandler Maintains Neutral on GRAIL, Raises Price Target to $56 — benzinga May 6, 2026 positive
- NEWS GRAIL Q1 EPS $(2.29) Beats $(2.70) Estimate, Sales $39.832M Beat $38.881M Estimate — benzinga May 5, 2026 positive
- NEWS Earnings Scheduled For May 5, 2026 — benzinga May 5, 2026 neutral
Generated 2026-07-07T12:21:43Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductGalleri10-K Item 1A: 'Sales of Galleri accounted for a substantial majority of our revenue to date'
- HIGHpipelineGalleri PMA10-K Item 1A: 'Our NHS-Galleri Trial did not meet its stated primary endpoint, which may adversely affect our business, stock price, and ability to obtain regulatory approvals'
Material Events(8-K, last 90d)
- 2026-06-01Item 5.02MEDIUMOn June 1, 2026, GRAIL Board approved amended offer letter for Dr. Joshua Ofman as CEO, effective June 1, 2026. Annual base salary $800,000 with VCP target increased to 100% (from prior 60%). Amended offer letter supersedes prior arrangement. No prior CEO departure cited in this filing.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Unprofitable operations — net margin -253.2%. Quality floor flags this regardless of sector context.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $69.50: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 4.4/10. Specifically: High short interest: 17%; Below-average business quality; Rich valuation. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $64.12. Score 4.4/10, moderate confidence.
Take-profit target: $69.98 (+1.5% upside). Prior stop was $64.12. Stop-loss: $64.12.
Concentration risk — Product: Galleri; Concentration risk — Pipeline: Galleri PMA; Target reached (-16.7% upside).
GRAIL, Inc. trades at a P/E of N/A (forward -7.1). TrendMatrix value score: 1.8/10. Verdict: Sell.
15 analysts cover GRAL with a consensus score of 3.9/5. Average price target: $66.
What does GRAIL, Inc. do?GRAIL, Inc. sells Galleri, a multi-cancer early detection test that screens for cancer signals across 50+ types from a...
GRAIL, Inc. sells Galleri, a multi-cancer early detection test that screens for cancer signals across 50+ types from a single blood draw using targeted DNA methylation analysis. The company sold over 185,000 Galleri tests in 2025 (475,000+ since the mid-2021 launch), with Galleri constituting substantially all revenue; a PMA for FDA approval was submitted in January 2026.